ABL1/2 and DDR1 Drive MEKi Resistance in NRAS-Mutant Melanomas by Stabilizing RAF/MYC/ETS1 and Promoting RAF Homodimerization

ABL1/2 and DDR1 Drive MEKi Resistance in NRAS-Mutant Melanomas by Stabilizing RAF/MYC/ETS1 and Promoting RAF Homodimerization

Melanomas harboring <i>NRAS</i> mutations are a particularly aggressive and deadly subtype. If patients cannot tolerate or the melanomas are insensitive to immune checkpoint blockade, there are no effective 2nd-line treatment options. Drugs targeting the RAF/MEK/ERK pathway, which are us...

Full description

Bibliographic Details
Main Authors: Anastasia Lyon, Rakshamani Tripathi, Christina Meeks, Daheng He, Yuanyuan Wu, Jinpeng Liu, Chi Wang, Jing Chen, Haining Zhu, Sujata Mukherjee, Saptadwipa Ganguly, Rina Plattner
Format: Article
Language:English
Published: MDPI AG 2023-02-01
Series:Cancers
Subjects:
whole exome sequencing
RNA sequencing
melanoma
NRAS
DDR1
ABL1
Online Access:https://www.mdpi.com/2072-6694/15/3/954

Internet

https://www.mdpi.com/2072-6694/15/3/954

Similar Items